SCHEMBL3562997

SCHEMBL3562997

COc1ncc(-c2ncc(OC)c3c(C(=O)C(=O)N4CCN(c5nnnn5-c5ccccn5)CC4)c[nH]c23)s1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C9 P11712 4/20 0.46
CYP3A4 P08684 2/20 0.46
CYP2C19 P33261 3/20 0.43
CYP2D6 P10635 2/20 0.43
CYP1A2 P05177 2/20 0.43
CYP2C8 P10632 1/20 0.43
CYP2B6 P20813 1/20 0.43
KCNH2 Q12809 1/20 0.43
ALDH1A1 P00352 12/20 0.37
KDM4E B2RXH2 9/20 0.37
HSD17B10 Q99714 6/20 0.37
TSHR P16473 2/20 0.37
HPGD P15428 2/20 0.37
KMT2A Q03164 2/20 0.35
MEN1 O00255 1/20 0.35
USP2 O75604 1/20 0.34
CDK5 Q00535 1/20 0.34
CDK5R1 Q15078 1/20 0.34
SMN1; SMN2 Q16637 2/20 0.33
MAPT P10636 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3558486 0.95 CYP2C9 (0.44) CYP2C9CYP3A4CYP2C19CYP2D6CYP1A2
SCHEMBL3565424 0.94 CYP2C9 (0.46) CYP2C9CYP3A4CYP2C19CYP2D6CYP1A2
SCHEMBL3557932 0.92 CYP2C9 (0.44) CYP2C9CYP3A4CYP2C19CYP2D6CYP1A2
SCHEMBL3564793 0.90 CYP3A4 (0.47) CYP2C9CYP3A4CYP2C19CYP2D6CYP1A2
SCHEMBL3562670 0.89 CYP2C9 (0.45) CYP2C9CYP3A4CYP2C19CYP2D6CYP1A2
SCHEMBL3559201 0.88 CYP3A4 (0.51) CYP2C9CYP3A4CYP2C19CYP2D6CYP1A2
SCHEMBL13120166 0.88 CYP2C9 (0.46) CYP2C9CYP3A4CYP2C19CYP2D6CYP1A2
SCHEMBL13120136 0.87 CYP2C9 (0.49) CYP2C9CYP3A4CYP2C19CYP2D6CYP1A2
SCHEMBL3566645 0.87 CYP2C9 (0.46) CYP2C9CYP3A4CYP2C19CYP2D6CYP1A2
SCHEMBL13120164 0.87 CYP2C9 (0.49) CYP2C9CYP3A4CYP2C19CYP2D6CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7807676-B2 Diketo-Piperazine and Piperidine derivatives as antiviral agents BRISTOL-MYERS SQUIBB COMPANY (US) 2010-10-05 US disclosed
US-7807676-B2 Diketo-Piperazine and Piperidine derivatives as antiviral agents BRISTOL-MYERS SQUIBB COMPANY (US) 2010-10-05 US disclosed
US-20080139572-A1 DIKETO-PIPERAZINE AND PIPERIDINE DERIVATIVES AS ANTIVIRAL AGENTS BRISTOL-MYERS SQUIBB COMPANY 2008-06-12 US disclosed
US-20080139572-A1 DIKETO-PIPERAZINE AND PIPERIDINE DERIVATIVES AS ANTIVIRAL AGENTS BRISTOL-MYERS SQUIBB COMPANY 2008-06-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080139572-A1 DIKETO-PIPERAZINE AND PIPERIDINE DERIVATIVES AS ANTIVIRAL AGENTS EIF2AK2, DCK, MAVS CYP2C9 3136/4885CYP3A4 1204/4885CYP2C19 2120/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.